BioXcel extends debt repayment deadline to Aug 28, 2026 via Thirteenth Amendment

BioXcel Therapeutics, Inc.

Thirteenth Amendment dated Aug 21, 2026 extends deadline from Aug 21 to Aug 28, 2026 for definitive agreements.
Company must enter transactions for full repayment of all obligations or alternative capital solutions acceptable to lenders.
Obligors must consider lender comments on regulatory processes involving material assets through Aug 28, 2026.
All other Credit Agreement terms remain in effect; no waiver of lender rights or remedies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.